Hip

If you’re of a certain vintage, if your bones are osteoporotic and you suffer a hip fracture, you are at risk of suffering one on the other side. In a piece of potentially smart-thinking a Bordeaux company has a minimally invasive device that might protect you against that eventuality.

Case number 2. Only 10,748 to go. This time its Chicago and one Carol Strum vs DePuy. Early shots suggest they’re aiming at punitive damages based on the assertion that DePuy knew of the design flaws in its product before Ms Strum had one implanted in her.

Steven Ek has been named ArthroSurface’s President and Chief Executive Officer, effective November 20, 2012. Mr. Ek is one of the original founders in Arthrosurface and a Director since inception.

Law firm, Legal Bay has issued this release following the jury’s massive award to Loren Kransky, plaintiff against J&J DePuy. It’s predicting many many more such cases.

Loren Kransky has been awarded over $8M in his lawsuit against J&J Depuy over the ASR hip prosthesis. J&J won’t know whether to laugh or cry right now. At least Mr Kransky wasn’t awarded punitive damages, but future cases might challenge that finding again..and again.

ArthroCare® Corp. has received clearance from the U.S. FDA for its SpeedLock® HIP Knotless Fixation implant. SpeedLock HIP is a PEEK implant that is indicated for soft tissue fixation to bone in the hip.

Here’s an update on the court case currently underway in the U.S. which may prove a bellwether for future proceedings … continue reading “Kransky vs J&J DePuy Trial Closing Remarks”

So did chromium from wear particles in DePuy’s ASR hip system poison Mr Kransky? A prominent toxicologist says no, but then his work is undermined by the plaintiff’s attorney who implies bias. It’s feisty stuff.

UK hip surgeon Jon Conroy thinks Lady Gaga’s imminent surgery will help raise the worldwide profile of pioneering minimally invasive hip surgery.

Yet again it’s registry data that has provoked a recall, this time of DePuy’s erstwhile Adept modular femoral component, which forms part of the all metal system originally sourced from Finsbury Orthopaedics Ltd.

According to a new report , published in “Value in Health”, delaying Total Hip Replacement surgery in people with osteoarthritis as a way to cut costs is ineffective and denies patients the benefits of an active and healthy life.

Even without the revenue following the acquisition of DePuy’s trauma business, Biomet’s SET products showed impressive double digit growth. Joints nudged up too, but it’s SET that has underpinned the company’s positive sales momentum.

Update on proceedings between “vasculopath” Loren Kransky and J&J (DePuy), centring on whether the company poisoned the plaintiff.

DePuy staff are still sounding defiant, but it’s not looking like the engineering group looked under every rock in establishing the safety and longevity of their ASR device. And then, when warned of issues, the claim is that the company didn’t act quickly enough.

More coverage from the trial between Kransky and DePuy has the all-metal hip maker feeling the heat from revelations that it hid the building concerns of orthopaedic surgeons about its device for a long time before the eventual recall.

Bloomberg has reported on the pre-trial testimony of Paul Voorhorst, a DePuy biostatistician, as a preamble to proceedings in the case of Loren Kransky vs J&J (DePuy), for which the jury sits tomorrow (Friday 25th January). In it, previously unseen documents suggest that the company’s own estimates of failure rate for some of its metal-on-metal hip prostheses are now as high as 37%, significantly higher than the 12 or 13% cited in the original recall notices.